Platelet levels and age are determinants of survival after mild-moderate TBI: A prospective study in Spain.


Journal

Frontiers in public health
ISSN: 2296-2565
Titre abrégé: Front Public Health
Pays: Switzerland
ID NLM: 101616579

Informations de publication

Date de publication:
2023
Historique:
received: 27 11 2022
accepted: 14 02 2023
medline: 7 4 2023
entrez: 6 4 2023
pubmed: 7 4 2023
Statut: epublish

Résumé

Traumatic brain injury (TBI) is a very important reason for consultation in emergency departments. A hospital cohort study with patients who attended a hospital emergency department between June 1, 2018 and December 31, 2020 due to TBI was studied. Clinical and sociodemographic variables were recorded. The levels of biomarkers and management variables were used. Qualitative variables were analyzed using Pearson's chi-square test, and quantitative variables using the Mann-Whitney A total of 540 patients were included. The mean age was 83 years, and 53.9% of the patients were men. Overall, 112 patients (20.7%) died during the study follow-up. The mortality rate per 100 person-years was 14.33 (11.8-17.24), the most frequent mechanism being falls in the home, with none caused on public roads. The multivariable Cox proportional hazards model showed that survival after TBI was significantly associated with age, S100 levels, Charlson index, patient's institutionalized status, the place where the TBI occurred, and hemoglobin and platelet levels. The most common profile for a patient with a TBI was male and aged between 80 and 90 years. The combination of the variables age, Charlson index, place of TBI occurrence, and hemoglobin and platelet levels could offer early prediction of survival in our population independently of TBI severity. With the data obtained, a therapeutic algorithm could be established for patients suffering from mild TBI, allowing the patient to be supervised at home, avoiding futile referrals to emergency services.

Identifiants

pubmed: 37020814
doi: 10.3389/fpubh.2023.1109426
pmc: PMC10067594
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1109426

Informations de copyright

Copyright © 2023 Yuguero, Vena, Bernal, Martínez-Alonso, Farre and Purroy.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

JAMA Neurol. 2022 Nov 1;79(11):1122-1129
pubmed: 36066882
Neurologia (Engl Ed). 2019 May 29;:
pubmed: 31153686
Brain Inj. 2022 Dec 6;36(12-14):1340-1348
pubmed: 36317233
J Am Geriatr Soc. 2006 Oct;54(10):1590-5
pubmed: 17038079
J Neurotrauma. 2021 Sep 15;38(18):2490-2501
pubmed: 33899510
Clin Lab. 2011;57(7-8):587-97
pubmed: 21888023
Rev Neurol. 2001 Feb 16-28;32(4):351-64
pubmed: 11333393
Scand J Trauma Resusc Emerg Med. 2023 Jan 10;31(1):3
pubmed: 36624501
Neurocirugia (Astur : Engl Ed). 2018 Sep - Oct;29(5):233-239
pubmed: 29898869
Childs Nerv Syst. 2019 Feb;35(2):343-348
pubmed: 30171330
Lancet Neurol. 2022 Sep;21(9):792-802
pubmed: 35963262
MMWR Morb Mortal Wkly Rep. 2020 Mar 06;69(9):225-230
pubmed: 32134910
MMWR Surveill Summ. 2017 Mar 17;66(9):1-16
pubmed: 28301451
Cureus. 2021 Aug 10;13(8):e17056
pubmed: 34522534
J Neurotrauma. 2018 Apr 1;35(7):889-906
pubmed: 29212411
J Neurotrauma. 2021 Dec;38(23):3295-3305
pubmed: 34605668
Injury. 2022 Aug;53(8):2774-2782
pubmed: 35725508
Lancet Neurol. 2017 Aug;16(8):630-647
pubmed: 28721927
Neurologia (Engl Ed). 2022 Jun;37(5):383-389
pubmed: 35672125
Front Med (Lausanne). 2022 Nov 11;9:916602
pubmed: 36438043
J Surg Res. 2013 May 1;181(1):16-9
pubmed: 22683074
Surg Clin North Am. 2017 Oct;97(5):1015-1030
pubmed: 28958355
Emerg Med J. 2017 Aug;34(8):509-516
pubmed: 28052919
Acta Neurochir (Wien). 2022 Oct;164(10):2731-2740
pubmed: 35838800
Surg Neurol Int. 2018 Jan 22;9(Suppl 1):S16-S28
pubmed: 29430327
Injury. 2009 Sep;40(9):973-7
pubmed: 19540490

Auteurs

Oriol Yuguero (O)

ERLab Emergency Research Group, Institute for Biomedical Research Dr. Pifarré Foundation, IRBLleida, Universitat de Lleida, Lleida, Spain.
Faculty of Medicine, University of Lleida, Lleida, Spain.

Ana Vena (A)

ERLab Emergency Research Group, Institute for Biomedical Research Dr. Pifarré Foundation, IRBLleida, Universitat de Lleida, Lleida, Spain.
Faculty of Medicine, University of Lleida, Lleida, Spain.

Maria Bernal (M)

Clinical Laboratory, University Hospital Arnau de Vilanova, Lleida, Spain.

Montserrat Martínez-Alonso (M)

Systems Biology and Statistical Methods for Biomedical Research Group, Institute for Biomedical Research Dr. Pifarré Foundation, IRBLleida, Universitat de Lleida, Lleida, Spain.

Joan Farre (J)

Clinical Laboratory, University Hospital Arnau de Vilanova, Lleida, Spain.

Francisco Purroy (F)

Faculty of Medicine, University of Lleida, Lleida, Spain.
Neurosciences Group, Institute for Biomedical Research Dr. Pifarré Foundation, IRBLleida, Universitat de Lleida, Lleida, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH